Adverse cardiac events associated with incident opioid drug use among older adults with COPD
We evaluated whether incident opioid drug use was associated with adverse cardiac events among older adults with chronic obstructive pulmonary disease (COPD).
This was an exploratory, retrospective cohort study using health administrative data from Ontario, Canada, from 2008 to 2013. Using a validated algorithm, we identified adults aged 66 years and older with non-palliative COPD. Hazard ratios (HR) were estimated for adverse cardiac events within 30 days of incident opioid receipt compared to controls using inverse probability of treatment weighting using the propensity score.
There were 134,408 community-dwelling individuals and 14,685 long-term care residents with COPD identified, 67.0 and 60.6% of whom received an incident opioid. Incident use of any opioid was associated with significantly decreased rates of emergency room (ER) visits and hospitalizations for congestive heart failure (CHF) among community-dwelling older adults (HR 0.84; 95% CI 0.73–0.97), but significantly increased rates of ischemic heart disease (IHD)-related mortality among long-term care residents (HR 2.15; 95% CI 1.50–3.09). In the community-dwelling group, users of more potent opioid-only agents without aspirin or acetaminophen combined had significantly increased rates of ER visits and hospitalizations for IHD (HR 1.38; 95% CI 1.08–1.77) and IHD-related mortality (HR 1.83; 95% CI 1.32–2.53).
New opioid use was associated with elevated rates of IHD-related morbidity and mortality among older adults with COPD. Adverse cardiac events may need to be considered when administering new opioids to older adults with COPD, but further studies are required to establish if the observed associations are causal or related to residual confounding.
KeywordsOpioids COPD Cardiac Pharmacoepidemiology Drug safety
NTV, XW, PAC, DSL, ALS, DEO, SSG and PAR contributed substantially to the study design, data analysis and interpretation and the writing of the manuscript.
Compliance with ethical standards
This study was approved by the review ethics board at Sunnybrook Health Sciences Centre.
Conflicts of interest
All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare the following: NTV had support from Godfrey S. Pettit Respirology Block Term Grant for the submitted work; XW, PAC, DSL, ALS, DEO, SSG and PAR had no support from any organization for the submitted work; DEO received grants and personal fees from Boehringer Ingelheim, grants and personal fees from Astra Zeneca, grants from GlaxoSmithKline and personal fees from Novartis, in the previous 3 years; NTV, XW, PAC, DSL, ALS, DEO, SSG and PAR had no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; and NTV, XW, PAC, DSL, ALS, DEO, SSG and PAR had no other relationships or activities that could appear to have influenced the submitted work.
This research was funded by a Godfrey S. Pettit Respirology Block Term Grant. This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. Parts of this material are based on data and information provided by Cancer Care Ontario (CCO). The opinions, results, view and conclusions reported in this paper are those of the authors and do not necessarily reflect those of CCO. No endorsement by CCO is intended or should be inferred. We thank Brogan Inc., Ottawa for use of their Drug Information Database. P.C. Austin was supported in part by a Career Investigator Award from the Heart and Stroke Foundation. D.S. Lee was supported by a mid-career investigator award from the Heart and Stroke Foundation and is the Ted Rogers Chair in Heart Function Outcomes.
- 6.Schultz JE, Rose E, Yao Z, Gross GJ (1995) Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Phys 268:H2157–H2161Google Scholar
- 8.Okubo S, Tanabe Y, Takeda K, Kitayama M, Kanemitsu S, Kukreja RC et al (2004) Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: role of delta-opioid receptor. Am J Physiol Heart Circ Physiol 287:H1786–H1791CrossRefPubMedGoogle Scholar
- 11.Jennings DB, Sparling J (1974) Effects of low O2 and high CO2 on cardiorespiratory function in conscious resting dogs. Am J Phys 226:431–438Google Scholar
- 26.Tu K, Mitiku T, Lee DS, Guo H, Tu JV (2010) Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD). Can J Cardiol 26:e225–e228CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators et al (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363:1128–1138CrossRefPubMedGoogle Scholar
- 34.Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ et al (1996) Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154:959–967CrossRefPubMedGoogle Scholar
- 35.O’Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D et al (2008) Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update—highlights for primary care. Can Respir J 15S:1A–8AGoogle Scholar
- 36.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016 (Accessed October 2016).Google Scholar